Etzer Darout
Stock Analyst at Barclays
(4.59)
# 238
Out of 5,147 analysts
166
Total ratings
53.33%
Success rate
29.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CCCC C4 Therapeutics | Maintains: Overweight | $5 → $7 | $2.70 | +159.26% | 7 | Feb 27, 2026 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Overweight | $224 | $190.02 | +17.88% | 1 | Feb 27, 2026 | |
| XNCR Xencor | Maintains: Overweight | $26 → $27 | $12.77 | +111.43% | 9 | Feb 26, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $108 → $113 | $92.08 | +22.72% | 6 | Feb 26, 2026 | |
| VIR Vir Biotechnology | Maintains: Overweight | $26 → $30 | $9.09 | +230.03% | 1 | Feb 25, 2026 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $10 → $11 | $3.86 | +184.97% | 3 | Feb 25, 2026 | |
| INCY Incyte | Maintains: Overweight | $116 → $117 | $101.27 | +15.53% | 3 | Feb 18, 2026 | |
| EXEL Exelixis | Maintains: Equal-Weight | $41 → $44 | $44.06 | -0.14% | 6 | Feb 4, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $8 → $10 | $5.37 | +86.22% | 14 | Feb 4, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $119 → $133 | $91.35 | +45.59% | 5 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $58 | $57.98 | +0.03% | 4 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $28 | $18.26 | +53.34% | 2 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $78 | $55.05 | +41.69% | 4 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $52 | $44.27 | +17.46% | 8 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $29 | $13.61 | +113.08% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $24 | $30.09 | -20.24% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $18 | $13.27 | +35.64% | 7 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $18 | $16.59 | +8.50% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $56 | $42.12 | +32.95% | 11 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $35 | $21.71 | +61.22% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $28 | $8.73 | +220.73% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $61 | $3.99 | +1,428.82% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $48 | $34.41 | +39.49% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $54.81 | +128.08% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $142 | $121.28 | +17.08% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $3 | $1.99 | +50.75% | 10 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $13 | $6.49 | +100.31% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 → $143 | $110.23 | +29.73% | 4 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $22 → $3 | $4.56 | -34.21% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $15.97 | +119.16% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $1.38 | +4,465.22% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $1.51 | +1,688.08% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $101.95 | +31.44% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $29.44 | +63.04% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $168.62 | -28.83% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.48 | +305.41% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $208.45 | -60.66% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $5.68 | +234.51% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $332.92 | -48.94% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $92.29 | -58.83% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $2.87 | +1,711.85% | 1 | Mar 28, 2018 |
C4 Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $5 → $7
Current: $2.70
Upside: +159.26%
Jazz Pharmaceuticals
Feb 27, 2026
Initiates: Overweight
Price Target: $224
Current: $190.02
Upside: +17.88%
Xencor
Feb 26, 2026
Maintains: Overweight
Price Target: $26 → $27
Current: $12.77
Upside: +111.43%
Protagonist Therapeutics
Feb 26, 2026
Maintains: Overweight
Price Target: $108 → $113
Current: $92.08
Upside: +22.72%
Vir Biotechnology
Feb 25, 2026
Maintains: Overweight
Price Target: $26 → $30
Current: $9.09
Upside: +230.03%
Iovance Biotherapeutics
Feb 25, 2026
Maintains: Overweight
Price Target: $10 → $11
Current: $3.86
Upside: +184.97%
Incyte
Feb 18, 2026
Maintains: Overweight
Price Target: $116 → $117
Current: $101.27
Upside: +15.53%
Exelixis
Feb 4, 2026
Maintains: Equal-Weight
Price Target: $41 → $44
Current: $44.06
Upside: -0.14%
CytomX Therapeutics
Feb 4, 2026
Maintains: Overweight
Price Target: $8 → $10
Current: $5.37
Upside: +86.22%
Kymera Therapeutics
Jan 28, 2026
Maintains: Overweight
Price Target: $119 → $133
Current: $91.35
Upside: +45.59%
Jan 21, 2026
Downgrades: Equal-Weight
Price Target: $58
Current: $57.98
Upside: +0.03%
Jan 21, 2026
Maintains: Overweight
Price Target: $16 → $28
Current: $18.26
Upside: +53.34%
Jan 20, 2026
Maintains: Overweight
Price Target: $55 → $78
Current: $55.05
Upside: +41.69%
Dec 17, 2025
Maintains: Overweight
Price Target: $45 → $52
Current: $44.27
Upside: +17.46%
Dec 17, 2025
Maintains: Overweight
Price Target: $48 → $29
Current: $13.61
Upside: +113.08%
Dec 17, 2025
Maintains: Underweight
Price Target: $21 → $24
Current: $30.09
Upside: -20.24%
Dec 17, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $13.27
Upside: +35.64%
Dec 17, 2025
Upgrades: Equal-Weight
Price Target: $16 → $18
Current: $16.59
Upside: +8.50%
Dec 9, 2025
Maintains: Overweight
Price Target: $36 → $56
Current: $42.12
Upside: +32.95%
Nov 24, 2025
Maintains: Overweight
Price Target: $22 → $35
Current: $21.71
Upside: +61.22%
Nov 24, 2025
Maintains: Overweight
Price Target: $11 → $28
Current: $8.73
Upside: +220.73%
Oct 13, 2025
Initiates: Overweight
Price Target: $61
Current: $3.99
Upside: +1,428.82%
Oct 13, 2025
Initiates: Overweight
Price Target: $48
Current: $34.41
Upside: +39.49%
Oct 13, 2025
Initiates: Overweight
Price Target: $125
Current: $54.81
Upside: +128.08%
Oct 13, 2025
Initiates: Overweight
Price Target: $142
Current: $121.28
Upside: +17.08%
Sep 17, 2025
Assumes: Overweight
Price Target: $3
Current: $1.99
Upside: +50.75%
Sep 2, 2025
Maintains: Buy
Price Target: $9 → $13
Current: $6.49
Upside: +100.31%
Mar 11, 2025
Maintains: Outperform
Price Target: $130 → $143
Current: $110.23
Upside: +29.73%
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $4.56
Upside: -34.21%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $15.97
Upside: +119.16%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $1.38
Upside: +4,465.22%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $1.51
Upside: +1,688.08%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $101.95
Upside: +31.44%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $29.44
Upside: +63.04%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $168.62
Upside: -28.83%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.48
Upside: +305.41%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $208.45
Upside: -60.66%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $5.68
Upside: +234.51%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $332.92
Upside: -48.94%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $92.29
Upside: -58.83%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $2.87
Upside: +1,711.85%